Privia Health Group, Inc. (NASDAQ:PRVA – Get Rating) has received an average rating of “Buy” from the sixteen analysts that are currently covering the firm, MarketBeat.com reports. Eleven research analysts have rated the stock with a buy recommendation. The average twelve-month price target among analysts that have covered the stock in the last year is $39.19.
A number of research analysts recently weighed in on PRVA shares. The Goldman Sachs Group assumed coverage on shares of Privia Health Group in a research report on Friday, February 3rd. They set a “buy” rating and a $32.00 price objective on the stock. Credit Suisse Group reaffirmed an “outperform” rating and issued a $41.00 price objective on shares of Privia Health Group in a research note on Tuesday, March 7th. SVB Securities lifted their price objective on shares of Privia Health Group from $39.00 to $40.00 in a research report on Friday, May 5th. Stephens began coverage on shares of Privia Health Group in a research note on Tuesday, April 11th. They issued an “overweight” rating and a $33.00 price target on the stock. Finally, Royal Bank of Canada assumed coverage on shares of Privia Health Group in a research note on Thursday, March 9th. They set an “outperform” rating and a $36.00 price target on the stock.
Privia Health Group Price Performance
PRVA stock opened at $25.24 on Friday. The company has a market cap of $2.92 billion, a P/E ratio of 229.45, a PEG ratio of 3.17 and a beta of 0.77. The firm has a 50-day moving average of $26.98 and a 200 day moving average of $26.06. Privia Health Group has a 1 year low of $20.64 and a 1 year high of $44.64.
Insider Buying and Selling
In other news, major shareholder Advisors L.L.C. Mbd sold 24,819,473 shares of the business’s stock in a transaction that occurred on Monday, May 8th. The stock was sold at an average price of $21.61, for a total transaction of $536,348,811.53. Following the transaction, the insider now directly owns 110,337 shares in the company, valued at approximately $2,384,382.57. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Privia Health Group news, Director William M. Sullivan sold 18,153 shares of Privia Health Group stock in a transaction dated Friday, May 12th. The stock was sold at an average price of $26.54, for a total transaction of $481,780.62. Following the completion of the sale, the director now directly owns 5,673,861 shares of the company’s stock, valued at approximately $150,584,270.94. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Advisors L.L.C. Mbd sold 24,819,473 shares of the stock in a transaction on Monday, May 8th. The shares were sold at an average price of $21.61, for a total transaction of $536,348,811.53. Following the completion of the transaction, the insider now directly owns 110,337 shares in the company, valued at $2,384,382.57. The disclosure for this sale can be found here. Over the last three months, insiders have sold 25,371,773 shares of company stock valued at $551,840,171. Corporate insiders own 44.80% of the company’s stock.
Institutional Trading of Privia Health Group
Several large investors have recently bought and sold shares of PRVA. Signaturefd LLC purchased a new position in shares of Privia Health Group in the 3rd quarter worth $32,000. HighMark Wealth Management LLC boosted its position in Privia Health Group by 46.1% during the 1st quarter. HighMark Wealth Management LLC now owns 1,315 shares of the company’s stock worth $36,000 after acquiring an additional 415 shares during the period. Assetmark Inc. increased its stake in Privia Health Group by 35.2% during the 3rd quarter. Assetmark Inc. now owns 1,207 shares of the company’s stock valued at $41,000 after buying an additional 314 shares during the period. Focused Wealth Management Inc acquired a new stake in Privia Health Group in the fourth quarter worth approximately $41,000. Finally, James Investment Research Inc. acquired a new position in Privia Health Group during the first quarter worth about $44,000. Institutional investors and hedge funds own 66.83% of the company’s stock.
About Privia Health Group
Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.
- Get a free copy of the StockNews.com research report on Privia Health Group (PRVA)
- It’s Time To Take Another Bite Of Take-Two Interactive
- Zoetis Declares New Dividend, Hinting At Undervaluation
- Good News For Walmart Isn’t So Great For Everybody Else
- Eagle Materials, Answering America’s Building Supply Needs
- Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market
Receive News & Ratings for Privia Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Privia Health Group and related companies with MarketBeat.com's FREE daily email newsletter.